ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,431.60
-0.04%
Dow Jones
38,589.16
-0.15%
US Dollar vs MXN
18.4648
0.00%
Brent Oil
82.275
0.00%
Bitcoin
66,579.92
0.59%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. NRX Pharmaceuticals Inc (NRXP)

  7. NRX Pharmaceuticals Inc (NRXP) Noticias

NRXP

NRX Pharmaceuticals (NRXP)

NRX Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:NRXP
FechaHoraFuenteTítuloSímboloCompañía
10/06/202407:30PR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update LetterNASDAQ:NRXPNRX Pharmaceuticals Inc
28/05/202407:30PR Newswire (US)NRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 is the First Oral Antidepressant Demonstrated to Reduce Suicidality in BipolaNASDAQ:NRXPNRX Pharmaceuticals Inc
14/05/202415:01PR Newswire (US)NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:NRXPNRX Pharmaceuticals Inc
08/05/202407:30PR Newswire (US)NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024NASDAQ:NRXPNRX Pharmaceuticals Inc
07/05/202415:01PR Newswire (US)NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024NASDAQ:NRXPNRX Pharmaceuticals Inc
06/05/202407:30PR Newswire (US)NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar DepressionNASDAQ:NRXPNRX Pharmaceuticals Inc
30/04/202407:30PR Newswire (US)NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar DepressionNASDAQ:NRXPNRX Pharmaceuticals Inc
18/04/202407:32PR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price RequirementNASDAQ:NRXPNRX Pharmaceuticals Inc
18/04/202407:30PR Newswire (US)NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common StockNASDAQ:NRXPNRX Pharmaceuticals Inc
17/04/202415:45PR Newswire (US)NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common StockNASDAQ:NRXPNRX Pharmaceuticals Inc
17/04/202407:30PR Newswire (US)NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infectionsNASDAQ:NRXPNRX Pharmaceuticals Inc
15/04/202407:30PR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)NASDAQ:NRXPNRX Pharmaceuticals Inc
08/04/202407:30PR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar DepressionNASDAQ:NRXPNRX Pharmaceuticals Inc
01/04/202407:28PR Newswire (US)NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:NRXPNRX Pharmaceuticals Inc
28/03/202407:03PR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End HighlightsNASDAQ:NRXPNRX Pharmaceuticals Inc
28/03/202407:00PR Newswire (US)NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq ListingNASDAQ:NRXPNRX Pharmaceuticals Inc
26/03/202415:03PR Newswire (US)UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024NASDAQ:NRXPNRX Pharmaceuticals Inc
25/03/202407:30PR Newswire (US)NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UKNASDAQ:NRXPNRX Pharmaceuticals Inc
21/03/202415:02PR Newswire (US)NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024NASDAQ:NRXPNRX Pharmaceuticals Inc
21/03/202412:57PR Newswire (US)NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of ShareholdersNASDAQ:NRXPNRX Pharmaceuticals Inc
12/03/202406:49PR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short SalesNASDAQ:NRXPNRX Pharmaceuticals Inc
11/03/202416:16Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NRXPNRX Pharmaceuticals Inc
11/03/202407:30PR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)NASDAQ:NRXPNRX Pharmaceuticals Inc
06/03/202415:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRXPNRX Pharmaceuticals Inc
04/03/202407:30PR Newswire (US)NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar DepressionNASDAQ:NRXPNRX Pharmaceuticals Inc
01/03/202407:30PR Newswire (US)NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per ShareNASDAQ:NRXPNRX Pharmaceuticals Inc
28/02/202409:40Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NRXPNRX Pharmaceuticals Inc
27/02/202409:49PR Newswire (US)/C O R R E C T I O N -- NRx Pharmaceuticals, Inc./NASDAQ:NRXPNRX Pharmaceuticals Inc
27/02/202407:54PR Newswire (US)NRx Pharmaceuticals, Inc. Announces Pricing of $1.5 Million Underwritten Public Offering of Common Stock Together with investor Commitment for Additional $1 millionNASDAQ:NRXPNRX Pharmaceuticals Inc
26/02/202407:30PR Newswire (US)NRx Pharmaceuticals (Nasdaq:NRXP) Launches HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024NASDAQ:NRXPNRX Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:NRXP

Su Consulta Reciente

NASDAQI
KSZ
Settle KBW Nasdaq Capita...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados